Pralatrexate

Lymphoma

Jennifer AmengualSmall moleculePhase 1/2Dormant

CCC

48/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 65/ 100

Competitive context

289 Active assets in the Lymphoma cohort.

Asset / Sponsor	Phase	Rating
VINBLASTINE Intensity Therapeutics, Inc.	Phase 4	BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE The Lymphoma Academic Research Organisation	Phase 4	BBB
BLEOMYCIN Shandong Provincial Hospital	Phase 4	BB
VINCRISTINE SULFATE Inhye Ahn	Phase 3	BB
(+)-VINCRISTINE Beth Israel Deaconess Medical Center	Phase 4	BB

View all 50 →

Same molecule, other indications

Pralatrexate is also rated in:

peripheral T-cell lymphoma, not otherwise specifiedDormant

BBB

Indicative ·

74 / 100

angioimmunoblastic T-cell lymphomaDormant

BB

Indicative ·

66 / 100

Nodal Peripheral T-Cell Lymphoma With TFH PhenotypeDormant

BB

Indicative ·

66 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.